Y
Yutaka Nishiwaki
Researcher at Tokyo Medical University
Publications - 304
Citations - 25785
Yutaka Nishiwaki is an academic researcher from Tokyo Medical University. The author has contributed to research in topics: Lung cancer & Survival rate. The author has an hindex of 65, co-authored 303 publications receiving 24446 citations. Previous affiliations of Yutaka Nishiwaki include National Cancer Research Institute.
Papers
More filters
Journal ArticleDOI
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Tony Mok,Yi-Long Wu,Sumitra Thongprasert,Chih-Hsin Yang,Da Tong Chu,Nagahiro Saijo,Patrapim Sunpaweravong,Baohui Han,Benjamin Margono,Benjamin Margono,Yukito Ichinose,Yutaka Nishiwaki,Yuichiro Ohe,Jin Ji Yang,Busyamas Chewaskulyong,Haiyi Jiang,Emma Duffield,Claire Watkins,Alison Armour,Masahiro Fukuoka +19 more
TL;DR: Gefit inib is superior to carboplatin-paclitaxel as an initial treatment for pulmonary adenocarcinoma among nonsmokers or former light smokers in East Asia and the presence in the tumor of a mutation of the EGFR gene is a strong predictor of a better outcome with gefitinib.
Journal ArticleDOI
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
Masahiro Fukuoka,Seiji Yano,Giuseppe Giaccone,Tomohide Tamura,Kazuhiko Nakagawa,Jean-Yves Douillard,Yutaka Nishiwaki,Johan Vansteenkiste,Shinzoh Kudoh,Danny Rischin,Richard Eek,Takeshi Horai,Kazumasa Noda,Ichiro Takata,Egbert F. Smit,Steven D. Averbuch,Angela Macleod,A. Feyereislova,Rui Ping Dong,José Baselga +19 more
TL;DR: Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in patients with pretreated advanced non-small-cell lung cancer.
Journal ArticleDOI
Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung Cancer
Kazumasa Noda,Yutaka Nishiwaki,Masaaki Kawahara,Shunichi Negoro,Takahiko Sugiura,A. Yokoyama,Masahiro Fukuoka,K. Mori,Koshiro Watanabe,Tomohide Tamura,Seiichiro Yamamoto,Nagahiro Saijo +11 more
TL;DR: Irinotecan plus cisplatin is an effective treatment for metastatic small-cell lung cancer and severe or life-threatening diarrhea was more frequent in the irinotican-plus-cisplatin group than in the etoposide-plus -cis Platin group.
Journal ArticleDOI
Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan
Yuichiro Ohe,Yasuo Ohashi,Kaoru Kubota,Tomohide Tamura,Kazuhiko Nakagawa,S. Negoro,Yutaka Nishiwaki,Nagahiro Saijo,Yutaka Ariyoshi,Masahiro Fukuoka +9 more
TL;DR: Four platinum-based combination regimens against cisplatin plus irinotecan have similar efficacy and different toxicity profiles, and they can be used to treat advanced NSCLC patients.
Journal ArticleDOI
Phase III Study of Concurrent Versus Sequential Thoracic Radiotherapy in Combination With Cisplatin and Etoposide for Limited-Stage Small-Cell Lung Cancer: Results of the Japan Clinical Oncology Group Study 9104
Minoru Takada,Masahiro Fukuoka,Masaaki Kawahara,Takahiko Sugiura,A. Yokoyama,Soichiro Yokota,Yutaka Nishiwaki,Koshiro Watanabe,Kazumasa Noda,Tomohide Tamura,Haruhiko Fukuda,Nagahiro Saijo +11 more
TL;DR: This study strongly suggests that cisplatin plus etoposide and concurrent radiotherapy is more effective for the treatment of LS-SCLC than cisPlatin plus Etoposid and sequential radiotherapy.